Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-26 is a potent inhibitor of the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway, exhibiting an IC50 of 0.0380 μM. This compound enhances the immune microenvironment by facilitating the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 is valuable for research applications focused on cancer immunotherapy and the modulation of immune responses in tumor biology. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-59 is a PD-1/PD-L1 inhibitor with an IC50 value of 183 nM. This compound is instrumental in the investigation of immune checkpoint regulation and has significant potential for research applications in triple-negative breast cancer (TNBC) therapies. By blocking the PD-1/PD-L1 interaction, it fosters immune response against tumor cells and facilitates the exploration of novel immunotherapeutic strategies. -
PD-L1 Inhibitor
PD-1/PD-L1-IN-60 is an inhibitor of PD-L1, a key checkpoint protein involved in immune evasion of tumors. This compound demonstrates significant anti-tumor activity in preclinical models, particularly within melanoma and lung cancer contexts where PD-L1 expression is elevated. PD-1/PD-L1-IN-60 is suitable for research applications focused on immunotherapy, tumor immune microenvironment studies, and the evaluation of therapeutic strategies targeting PD-L1. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-20 is a small-molecule inhibitor targeting the PD-1/PD-L1 protein-protein interaction, demonstrating an IC50 of 5.29 nM. This compound effectively disrupts the PD-1/PD-L1 pathway, making it a valuable tool for research in oncology, infectious diseases, and autoimmune disorders. Its ability to modulate immune checkpoint proteins provides significant insights into therapeutic strategies for enhancing anti-tumor immunity. -
PD-L1/PD-1 Inhibitor
PD-L1/PD-1-IN-1 is a potent inhibitor of the PD-L1/PD-1 interaction, demonstrating an IC50 of less than 1 nM. This compound is significant for research in anti-tumor therapies, facilitating the study of immune checkpoint modulation and its effects on tumor growth. Its ability to effectively block PD-L1 signaling makes it a valuable tool for exploring therapeutic strategies in cancer immunotherapy. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-19 is a small-molecule inhibitor targeting the PD-1/PD-L1 protein-protein interaction. With an IC50 of 62.3 nM, it effectively inhibits the binding of PD-1 to PD-L1, thereby modulating immune responses. This compound is suitable for research applications in cancer immunotherapy, as well as studies focused on infectious and autoimmune diseases. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-17 is a potent inhibitor of the PD-1/PD-L1 interaction, with an IC50 value of 26.8 nM. This compound serves as a valuable lead in the development of PD-1/PD-L1 inhibitors, making it an important tool for cancer research. Its ability to modulate immune checkpoint pathways highlights its potential in the exploration of cancer immunotherapy strategies. -
PD-1/PD-L1 Inhibitor
HBV/HDV-IN-1 is a potent inhibitor of PD-1/PD-L1 interactions, demonstrating EC50 values of 8 nM for T cell activation and 35 nM for PD-L1 internalization. This compound is essential for investigating the role of immune checkpoint modulation in hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. Its ability to enhance T cell responses makes it valuable for research in immunotherapy and viral pathogenesis. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-52 is an orally bioavailable inhibitor of the PD-1/PD-L1 interaction, demonstrating an IC50 of 109.9 nM. This compound exhibits significant antitumor effects, as evidenced by a tumor growth inhibition (TGI) of 49.6% in a C57BL/6 mouse xenograft model utilizing human PD-1-expressing MC38 colon cancer cells. Research applications include the exploration of immune checkpoint modulation and therapeutic strategies in cancer treatment. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-31 is a potent inhibitor of the PD-1/PD-L1 pathway, demonstrating an IC50 value of 2.2 nM. This compound enhances the secretion of interferon-gamma (IFN-γ) and stimulates the immune response of peripheral blood mononuclear cells (PBMCs), leading to the inhibition of tumor cell proliferation. PD-1/PD-L1-IN-31 is valuable for research applications focused on cancer immunotherapy and the modulation of immune checkpoints. -
PD-1/PD-L1 Inhibitor
PD-1-IN-25 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 10.2 nM as determined by HTRF assay. This compound enhances CD8+ T cell activation by disrupting PD-1/PD-L1 signaling pathways. PD-1-IN-25 demonstrates significant potential for delaying tumor growth, making it a valuable tool for cancer immunotherapy research. -
PD-1/PD-L1 Inhibitor
BMS-242 is a small molecule inhibitor targeting the PD-1/PD-L1 interaction. It effectively binds to the hydrophobic channel pocket of PD-L1, disrupting the PD-1/PD-L1 immune checkpoint pathway. This action enhances anti-tumor immunity, making BMS-242 a valuable tool for cancer research and therapeutic studies focused on immune modulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-24 is a potent inhibitor of the PD-1/PD-L1 pathway, exhibiting an IC50 value of 1.57 nM. This compound effectively restores T-cell function by significantly increasing the levels of IFN-γ at the cellular level. With low toxicity towards peripheral blood mononuclear cells (PBMCs), PD-1/PD-L1-IN-24 is suitable for research applications focused on cancer immunotherapy and autoimmunity studies. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-21 is a small-molecule inhibitor targeting the PD-1/PD-L1 protein-protein interaction, exhibiting an IC50 of 4.99 μM. This compound effectively blocks PD-1 and PD-L1, making it a valuable tool for research into cancer, infectious diseases, and autoimmune conditions. Its ability to disrupt this immune checkpoint pathway positions PD-1/PD-L1-IN-21 as a significant reagent for studies aimed at enhancing anti-tumor immunity and understanding immune responses. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-53 is a potent inhibitor of the PD-1/PD-L1 and VISTA signaling pathways. This compound is primarily utilized in anti-cancer research to investigate immune checkpoint mechanisms and enhance T-cell activation. PD-1/PD-L1-IN-53 provides valuable insights for studies focused on tumor microenvironments and immunotherapy responses. -
PD-L1/VISTA Inhibitor
PD-L1/VISTA-IN-1 is a potent dual-target inhibitor of programmed death ligand 1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA). This compound effectively disrupts the PD-1/PD-L1 interaction with an IC50 of 0.1492 μM and inhibits the VISTA pathway with a KD of 0.2723 μM, promoting T cell reactivation. PD-L1/VISTA-IN-1 demonstrates significant anti-tumor activity, making it a valuable tool for cancer immunotherapy research. -
PD-1/PD-L1 Inhibitor
HBV/HDV-IN-2 is a potent inhibitor of both hepatitis B virus (HBV) and hepatitis D virus (HDV), as well as the PD-1/PD-L1 pathway. It exhibits an EC50 of 35 nM for T cell activation, making it a valuable tool for investigating immune modulation in viral infections. This compound is applicable in research aimed at understanding the interplay between viral infections and immune checkpoint regulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-55 is a potent inhibitor targeting the PD-1/PD-L1 immune checkpoint pathway, exhibiting an IC50 of 4.8 nM. This compound enhances the secretion of IFN-γ and decreases the incidence of late apoptosis in PD-L1 expressing cells. PD-1/PD-L1-IN-55 is valuable for research applications in cancer therapy and immunology, particularly in studies aimed at restoring T-cell activation and modulating immune responses. -
PD-1/PD-L1 Inhibitor
PD1-PDL1-IN 2 is a potent and selective inhibitor of the PD-1/PD-L1 pathway. This compound demonstrates significant antitumor activity in vivo by promoting cytotoxic T-cell infiltration into tumors and inducing interleukin-2 (IL-2) expression. Additionally, PD1-PDL1-IN 2 strongly inhibits the mRNA expression of TGF-β, making it a valuable tool for research in cancer immunotherapy and the modulation of immune responses. -
PD-L1 Inhibitor
PD-L1-IN-7 is a potent inhibitor of programmed cell death ligand 1 (PD-L1), effectively disrupting the PD-1/PD-L1 interaction with an IC50 of 0.2 nM. This compound facilitates the internalization and retention of PD-L1 within cells, alters glycosylation patterns, and promotes PD-L1 degradation. PD-L1-IN-7 enhances T cell infiltration and boosts T cell cytotoxic function, making it a valuable tool for developing immunotherapeutic strategies against tumors. -
PD-1/PD-L1 Inhibitor
Human PD-L1 Inhibitor III is a selective inhibitor targeting the PD-1/PD-L1 pathway, which plays a critical role in immune evasion by tumors. By blocking the interaction between programmed cell death protein 1 (PD-1) and its ligand PD-L1, this compound enhances T-cell activity, promoting anti-tumor immune responses. It is valuable for researchers investigating cancer immunotherapy and assessing therapeutic strategies aimed at modulating immune checkpoint pathways. -
PD-L1 Inhibitor
PD-L1-IN-4 is a selective inhibitor of PD-L1, demonstrating potent inhibition of the PD-1/PD-L1 interaction with an IC50 value of 1.3 nM. This compound also enhances the PD-L1 inhibitory effect on T cells, with an EC50 of 152.8 nM. PD-L1-IN-4 is suitable for studies in cancer research, particularly in the context of immunotherapy and tumor microenvironment modulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-27 is a potent inhibitor of the PD-1/PD-L1 pathway, demonstrating an IC50 value of 134 nM. This compound exhibits significant antitumor activity while maintaining low cytotoxicity towards T cells. Additionally, PD-1/PD-L1-IN-27 effectively activates CD8+ T cells and mitigates T cell exhaustion, making it a valuable tool for immuno-oncology research applications. -
PD-1/PD-L1 Inhibitor
SWS1 is a d-(+)-biotin-conjugated inhibitor of PD-L1 with an IC50 of 1.8 nM. It has demonstrated significant anticancer activity by enhancing tumor-infiltrating lymphocyte populations and inducing anti-tumor effects in the B16-F10 mouse model, achieving a tumor growth inhibition rate of 66.1%. SWS1 is suitable for research applications focused on immunotherapy and tumor microenvironment studies. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-34 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 0.029 μM, and demonstrates a binding affinity towards PD-L1 with a KD of 0.1554 μM. This compound activates the immune microenvironment, showcasing significant anti-tumor activity which reinforces its potential in cancer immunotherapy research. PD-1/PD-L1-IN-34 is an invaluable tool for elucidating mechanisms of immune modulation and evaluating therapeutic strategies in oncology. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-28 is a potent inhibitor of the PD-1/PD-L1 signaling pathway, exhibiting an IC50 value of 0.744 µM. This compound demonstrates significant potential in the modulation of tumor immunity, making it a valuable reagent for cancer immunotherapy research. Its ability to disrupt immune checkpoint interactions positions PD-1/PD-L1-IN-28 as an important tool for studying immune responses in various tumor models. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-4 is a potent dual-target inhibitor of CYP51 and PD-L1, demonstrating IC50 values of 0.17 μM and 0.021 μM, respectively. This compound exhibits significant antifungal activity and is effective against drug-resistant fungal strains in vitro. CYP51/PD-L1-IN-4 is suitable for research applications focused on fungal infections and the interplay between fungal pathogens and immune checkpoint regulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-22 is a small-molecule inhibitor specifically targeting the PD-1/PD-L1 protein-protein interaction. With an IC50 value of 0.732 μM, it effectively disrupts this pathway, making it a valuable tool in cancer, infectious disease, and autoimmune disease research. Its ability to modulate immune responses positions PD-1/PD-L1-IN-22 as a significant compound for therapeutic development in immunooncology and related fields. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-18 is a small-molecule inhibitor that specifically targets the PD-1/PD-L1 protein-protein interaction, demonstrating an IC50 of 1.054 μM. This compound effectively blocks PD-1/PD-L1 signaling, facilitating enhanced T-cell activation and antitumor responses. It is valuable for research applications focused on immunotherapy and cancer treatment strategies. -
PD-L1 Inhibitor
PD-L1-IN-8 is a selective PD-L1 inhibitor with an IC50 of 0.89 nM. It demonstrates low inhibition of cytochrome P450 enzymes and minimal hERG activity, indicating a favorable safety profile. This compound is specifically useful in the investigation of PD-L1 mediated immune evasion in colon cancer research, contributing to the understanding of tumor-immune system interactions. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-25 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 16.17 nM. This compound effectively enhances T cell antitumor immunity in peripheral blood mononuclear cells (PBMCs). PD-1/PD-L1-IN-25 is instrumental for cancer research, particularly in studies focused on immunotherapy and tumor microenvironment modulation. -
PD-L1/CD-73 Inhibitor
PD-L1/CD-73-IN-1 is a potent inhibitor of PD-L1 and CD73, exhibiting IC50 values of 6 nM and 0.773 μM, respectively. This compound demonstrates significant biological activity by inhibiting tumor cell growth both in vitro and in vivo. It is an essential tool for research applications focused on immune modulation and cancer therapy. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-58 is a selective inhibitor of the PD-1/PD-L1 pathway, demonstrating a dissociation constant (KD) of 77.60 nM for PD-L1 in comparison to PD-1. This compound exhibits oral bioactivity and is particularly relevant for investigations into immune modulation and potential therapeutic strategies against influenza A virus. Its mechanism of action makes it a valuable tool for research aimed at understanding and manipulating immune responses in various disease contexts. -
PD-1/PD-L1 Inhibitor
LH1306 is a C2-symmetric inhibitor specifically targeting the PD-1/PD-L1 protein-protein interaction, demonstrating an IC50 value of 25 nM. This compound is pivotal for studies investigating immune checkpoint blockade and its potential applications in anti-tumor research. By modulating immune responses, LH1306 serves as a valuable tool for exploring therapeutic strategies in cancer immunotherapy. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-54 is an inhibitor of the PD-1/PD-L1 interaction, targeting immune checkpoints critical for tumor immune evasion. With a KD of 55.8 μM for PD-1 and 46.4 μM for PD-L1, and an IC50 of 88.6 μM, this compound enhances CD8+ T cell activation and promotes the secretion of key cytokines such as IFN-γ and IL-2. Furthermore, PD-1/PD-L1-IN-54 exhibits anticancer properties by inhibiting tumor cell proliferation and inducing apoptosis, while also modulating T cell immunity via the PI3K/Akt signaling pathway. -
CSE1L/PD-L1 Inhibitor
Naamidine J is an imidazole-type alkaloid that functions as a CSE1L/PD-L1 inhibitor. It demonstrates significant anti-inflammatory activity by reducing pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, while enhancing the expression of anti-inflammatory markers like CD206 and Arg-1. Additionally, Naamidine J exhibits antitumor properties and alleviates pulmonary tissue edema and inflammatory infiltrates in murine models. This compound is valuable for research focused on the immune microenvironment in the contexts of acute lung injury and cancer. -
PD-L1/HDAC6 Inhibitor
PD-L1/HDAC6-IN-1 is a dual inhibitor targeting PD-L1 and HDAC6, effectively disrupting the PD-L1/PD-1 interaction with IC50 values of 26.8 nM and 69 nM, respectively. This compound significantly enhances the cytotoxicity of Jurkat T cells against HepG2 cells with an IC50 of 3.4 μM. Additionally, PD-L1/HDAC6-IN-1 demonstrates favorable pharmacokinetics in rat models, achieving a drug exposure level of 871.62 ng·h/mL, and shows promising antitumor efficacy in B16-F10 xenograft models in mice. -
PD-L1/HDAC Inhibitor
PD-L1/HDAC-IN-1 is a dual inhibitor targeting PD-L1, HDAC2, and HDAC3, with IC50 values of 88.10 nM, 27.98 nM, and 14.47 nM, respectively. This compound effectively disrupts the PD-1/PD-L1 interaction and demonstrates minimal cytotoxicity in MCF-7 cells (IC50=19.34 μM). PD-L1/HDAC-IN-1 enhances the expression of PD-L1 and CXCL10, thereby facilitating an anti-tumor immune response through increased T-cell recruitment into the tumor microenvironment (TME). Its unique mechanism positions it as a valuable tool for research in cancer immunotherapy. -
PD-1/PD-L1 Interaction Inhibitor
PD-1/PD-L1-IN 3 is a macrocyclic peptide that acts as a selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions. By binding to PD-L1, it effectively disrupts the binding of PD-L1 to PD-1 and CD80, exhibiting IC50 values of 5.60 nM and 7.04 nM, respectively. This compound is valuable for research in various fields, particularly in cancer immunotherapy and the study of infectious diseases. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-10 is a potent orally active inhibitor of the PD-1/PD-L1 interaction, with an IC50 value of 2.7 nM. This compound exhibits significant anticancer efficacy by blocking the immune checkpoint pathway, thereby enhancing T-cell activation and promoting anti-tumor responses. PD-1/PD-L1-IN-10 is valuable for research in immunotherapy and cancer treatment studies. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-3 is a dual inhibitor targeting CYP51 and PD-L1, exhibiting potent antifungal activity with IC50 values of 0.205 μM and 0.039 μM, respectively. This compound induces early apoptosis in fungal cells by reducing levels of intracellular IL-2, NLRP3, and NF-κBp65 proteins. Additionally, CYP51/PD-L1-IN-3 causes mitochondrial damage and reactive oxygen species (ROS) accumulation, ultimately resulting in fungal lysis and cell death. This compound serves as a valuable tool for research in fungal infections and immune modulation. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-2 is a quinazoline compound that functions as a dual inhibitor of CYP51 and PD-L1, exhibiting IC50 values of 0.263 μM and 0.017 μM, respectively. It displays notable antifungal activity by triggering early apoptosis in fungal cells, leading to significant reductions in intracellular IL-2, NLRP3, and NF-κBp65 protein levels. Additionally, CYP51/PD-L1-IN-2 induces mitochondrial damage and reactive oxygen species (ROS) accumulation, culminating in fungal lysis and subsequent cell death. This compound is valuable for research exploring antifungal mechanisms and cancer immunotherapy. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-1 is a dual inhibitor targeting both CYP51 and PD-L1, exhibiting an IC50 of 0.884 μM for CYP51 and 0.083 μM for PD-L1. This quinazoline compound demonstrates notable antifungal activity by inducing early apoptosis in fungal cells while significantly reducing intracellular levels of IL-2, NLRP3, and NF-κBp65. Additionally, CYP51/PD-L1-IN-1 contributes to mitochondrial damage and reactive oxygen species (ROS) accumulation, ultimately leading to fungal lysis and cell death. This compound is valuable for research focused on antifungal therapies and immune modulation. -
CTLA-4/PD-L1 Inhibitor
Davoceticept is a fusion protein consisting of the CD80 (1-107) fragment linked to IGHG1 Fc via a peptidyl linker, targeting CTLA-4 and PD-L1. This variant CD80 vIgD-Fc acts as an immune checkpoint inhibitor, enhancing T cell activation and promoting anti-tumor responses. Its applications include cancer immunotherapy and studying immune modulation in various malignancies, making it a valuable tool for researchers investigating therapeutic strategies in cancer treatment.
